South Tulsa Pathology Laboratory, Inc. - Page 19




                                       - 19 -                                         
          Income Tax Regs., emphasizes that a distribution ordinarily will            
          not be considered to have been used principally as a device if              
          the distributing and controlled corporations have “no accumulated           
          earnings and profits at the beginning of their respective taxable           
          years” and “no current earnings and profits as of the date of the           
          distribution”.  (Emphasis added.)  Section 1.355-2(d)(5)(ii),               
          Income Tax Regs., does not provide a safe harbor for corporations           
          with “insignificant” or “minimal” earnings and profits, as                  
          petitioner contends.                                                        
               Second, petitioner ignores the fact that the spinoff enabled           
          it to claim that the substantial gain on the distribution of                
          Clinpath stock to its shareholders, which ordinarily would have             
          increased its current and accumulated earnings and profits, need            
          not be recognized for corporate income tax purposes or reflected            
          in the calculation of its earnings and profits as of October 30,            
          1993 and at yearend.  Respondent argues that, if the spinoff of             
          Clinpath did not qualify for tax-free treatment under sections              
          368 and 355, the distribution of Clinpath stock to petitioner’s             
          shareholders would be taxable under section 311(b) and,                     
          therefore, would have generated substantial current earnings and            
          profits to petitioner under section 312(b) as of October 30, the            
          date of the distribution.                                                   
               Neither party disputes that, if the spinoff of Clinpath                
          does not qualify as a tax-free transaction under sections 368 and           






Page:  Previous  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  Next

Last modified: May 25, 2011